Update in Infectious Diseases
Authors: Bennett Lorber
Journal: Annals of Internal Medicine (2002)

Updates from the Annual Session17 December 2002Update in Infectious DiseasesBennett Lorber, MDBennett Lorber, MDFrom Temple University Hospital, Philadelphia, Pennsylvania.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-137-12-200212170-00011 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail A look at the medical literature from 2001 affirms that infectious diseases remains one of the most changeable and exciting areas of clinical practice. The papers I review in this Update cover terrorist threats to the public health, new approaches to some old problems, newly recognized disorders and novel treatments for infection, HIV infection, and infectious complications of treatment for other illnesses.Biological TerrorismBioterrorism in the United States is no longer merely a threat but a reality; Americans ask not “What if?” but “What next?” Bioterrorism, as distinct from biological warfare, is an attempt not so much to kill ...References1. Manges AR, Johnson JR, Foxman B, O'Bryan TT, Fullerton KE, Riley LW. Widespread distribution of urinary tract infections caused by a multidrug-resistant Escherichia coli clonal group. N Engl J Med. 2001;345:1007-13. [PMID: 11586952] CrossrefMedlineGoogle Scholar2. Ledergerber B, Mocroft A, Reiss P, Furrer H, Kirk O, Bickel M, et al . Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N Engl J Med. 2001;344:168-74. [PMID: 11188837] CrossrefMedlineGoogle Scholar3. Tillmann HL, Heiken H, Knapik-Botor A, Heringlake S, Ockenga J, Wilber JC, et al . Infection with GB virus C and reduced mortality among HIV-infected patients. N Engl J Med. 2001;345:715-24. [PMID: 11547740] CrossrefMedlineGoogle Scholar4. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, et al . Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286:2568-77. [PMID: 11722271] CrossrefMedlineGoogle Scholar5. Deresinski S. Caspofungin: a novel antifungal agent. Infectious Diseases Alert. 2001;20:97-100. Google Scholar6. . Caspofungin (Cancidas) for aspergillosis. Med Lett Drugs Ther. 2001;43:58-9. [PMID: 11445777] MedlineGoogle Scholar7. Ascherio A, Zhang SM, Hernán MA, Olek MJ, Coplan PM, Brodovicz K, et al . Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med. 2001;344:327-32. [PMID: 11172163] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Temple University Hospital, Philadelphia, Pennsylvania.Corresponding Author: Bennett Lorber, MD, Section of Infectious Diseases, Temple University Hospital, Broad and Ontario Streets, Philadelphia, PA 19140; e-mail, [email protected]temple.edu. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byBioArena system for studying key molecules as well as ingredients in biological samplesBioArena: An unlimited possibility of biochemical interactions in the adsorbent layer after chromatographic separationLyme disease: a turning point 17 December 2002Volume 137, Issue 12Page: 974-980KeywordsAIDSDoxycyclineDrugsHIVHIV infectionsHepatitis G virusLiverMultiple sclerosisProphylaxisViral load ePublished: 17 December 2002 Issue Published: 17 December 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...